Biotechnology
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2024-06-02 08:00
3635
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-06-02 08:00
3047
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-06-02 08:00
4943
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cet...
2024-06-02 07:13
2920
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
CHICAGO, June 1, 2024 /PRNewswire/ -- On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for presentation at the 2024 American Society of Clinical Onc...
2024-06-02 03:00
1401
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress
in the construction of its alpaca-derived nanobody discovery platform,
ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully
replaced by alpaca IGH-VDJ genes in-situ.
2024-06-01 20:00
1499
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
* Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors * A 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day) *...
2024-06-01 20:00
3478
Hello Health Group (HHG) Welcomes 5i Ventures (5iV) as Leading Investor, Paving the Way for Future Growth
SINGAPORE, May 31, 2024 /PRNewswire/ -- Hello Health Group (HHG), the leading digital health and wellness platform inAsia, is pleased to announce the successful closing of theSingapore-based 5i Ventures (5iV) acquisition of a major stake in HHG. Following the transaction, 5iV will be the new lead...
2024-05-31 21:37
3889
Neurophet to participate BIO USA… exploring global partnership and business
* Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development * Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for...
2024-05-31 21:00
2634
SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of AKANTIOR® (polihexanide under the international non-proprietary name),...
2024-05-31 15:00
1588
One in Six Globally Concerned About Colorectal Cancer Screening Costs
SHENZHEN, China, May 31, 2024 /PRNewswire/ -- By 2040, the burden of colorectal
cancer (CRC) is projected to increase to 3.2 million new cases and 1.6 million
deaths per year representing a 66% and 71% rise in new cases and deaths
respectively relative to2020
2024-05-31 08:00
2600
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
* TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. * Reported median radiographic progression-free survival (rPFS) is 8.8 months. * Builds on prior data from th...
2024-05-31 07:19
2017
LumaCina announces availability of Oral Morphine pain medication for New Zealanders
PERTH, Australia and MIAMI, May 31, 2024 /PRNewswire/ -- LumaCina, the pharmaceutical supplier and marketing division ofBridgewest Perth Pharma announce new production of Oral Morphine to meet critical drug shortage inNew Zealand. The shortfall of Oral Morphine has become increasingly concerning...
2024-05-31 05:17
1886
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
* Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso * PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies * Full Data Set to be P...
2024-05-31 02:21
1938
OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases
SHANGHAI, May 30, 2024 /PRNewswire/ -- On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the "Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases" ...
2024-05-30 21:00
1959
Metabolon Announces 4-Week Turnaround Time for Commercial Projects, Enhancing Metabolomic Services for Multiomic Research
MORRISVILLE, N.C., May 30, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant enhancement to its serv...
2024-05-30 20:57
1342
Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, ap...
2024-05-30 17:09
1421
Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
HEIDELBERG, Germany , May 29, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical tr...
2024-05-30 08:00
1249
Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
* Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p<0.0096) * Multiple secondary endpoints met with significant total hair re...
2024-05-30 07:05
3371
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven m...
2024-05-29 22:00
1616
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5214
